Přejít k obsahu
Merck
Všechny fotografie(1)

Key Documents

View All Documentation

1078733

USP

Bupropion hydrochloride

United States Pharmacopeia (USP) Reference Standard

Synonyma:

(±)-1-(3-Chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone hydrochloride

Přihlásitk zobrazení cen stanovených pro organizaci a smluvních cen
Všechny fotografie(1)

About This Item

Empirický vzorec (Hillův zápis):
C13H18ClNO · HCl
Číslo CAS:
31677-93-7
Molekulová hmotnost:
276.20
MDL number:
MFCD00055209
UNSPSC Code:
41116107
PubChem Substance ID:
329749161
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

bupropion

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

Cl[H].CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1

InChI

1S/C13H18ClNO.ClH/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10;/h5-9,15H,1-4H3;1H

InChI key

HEYVINCGKDONRU-UHFFFAOYSA-N

Gene Information

human ... SLC6A2(6530) , SLC6A3(6531)

Hledáte podobné produkty? Navštivte Průvodce porovnáváním produktů

Související kategorie

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Bupropion hydrochloride USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Bupropion Hydrochloride Extended-Release Tablets
  • Bupropion Hydrochloride Tablets

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

Related product

Č. produktu
Popis
Stanovení ceny

1078744

Bupropion Hydrochloride Related Compound A, United States Pharmacopeia (USP) Reference Standard

1078755

Bupropion Hydrochloride Related Compound B, United States Pharmacopeia (USP) Reference Standard

1078766

Bupropion Hydrochloride Related Compound C, United States Pharmacopeia (USP) Reference Standard

1078799

Bupropion Hydrochloride Related Compound F, United States Pharmacopeia (USP) Reference Standard

1078846

Bupropion hydrobromide, United States Pharmacopeia (USP) Reference Standard

1112299

3-Chlorobenzoic acid, United States Pharmacopeia (USP) Reference Standard

PHR1744

3-Chlorobenzoic acid, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1752

Bupropion Hydrochloride Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1753

Bupropion Hydrochloride Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1755

Bupropion Related Compound F, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1754

Bupropion Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

1078857

Bupropion Related Compound G, United States Pharmacopeia (USP) Reference Standard

1117020

Chloropropiophenone, United States Pharmacopeia (USP) Reference Standard

PHR3178

Bupropion Hydrobromide, pharmaceutical secondary standard, certified reference material

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Osvědčení o analýze (COA)

Vyhledejte osvědčení Osvědčení o analýze (COA) zadáním čísla šarže/dávky těchto produktů. Čísla šarže a dávky lze nalézt na štítku produktu za slovy „Lot“ nebo „Batch“.

Již tento produkt vlastníte?

Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.

Navštívit knihovnu dokumentů

Zákazníci si také prohlíželi

Slide 1 of 5

1 of 5

Bupropion Related Compound C Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1754

Bupropion Related Compound C

(±)-Bupropion-D9 hydrochloride solution 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

B-052

(±)-Bupropion-D9 hydrochloride solution

(±)-Hydroxybupropion solution 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

H-066

(±)-Hydroxybupropion solution

Phenacetin ≥98.0% (HPLC)

Sigma-Aldrich

77440

Phenacetin

Diclofenac sodium salt

Sigma-Aldrich

D6899

Diclofenac sodium salt

M R Nichols
Clinical excellence for nurse practitioners : the international journal of NPACE, 3(6), 317-322 (2000-06-24)
All healthcare providers have an obligation to promote smoking cessation to their patients who smoke. While patients are advised to stop smoking, the use of specific smoking cessation strategies is rarely addressed by primary care providers. This article discusses smoking
Marlene P Freeman
The American journal of psychiatry, 171(7), 723-728 (2014-07-02)
Attention deficit hyperactivity disorder (ADHD) has been increasingly recognized and treated in children and adults in recent years. As a result, a growing number of women enter their reproductive years treated with medication for ADHD or are diagnosed and start
Patrick A Randall et al.
PloS one, 9(6), e99320-e99320 (2014-06-18)
Behavioral activation is a fundamental feature of motivation, and organisms frequently make effort-related decisions based upon evaluations of reinforcement value and response costs. Furthermore, people with major depression and other disorders often show anergia, psychomotor retardation, fatigue, and alterations in
Sergios Charntikov et al.
Neuropharmacology, 86, 181-191 (2014-08-01)
Bupropion is an atypical antidepressant that increases long-term quit rates of tobacco smokers. A better understanding of the relation between nicotine and this first-line medication may provide insight into improving treatment. For all experiments, rats first had nicotine (0.4 mg base/kg)
Theresa M Winhusen et al.
The Journal of clinical psychiatry, 75(4), 336-343 (2013-12-19)
To evaluate the impact of concurrent treatments for substance use disorder and nicotine-dependence for stimulant-dependent patients. A randomized, 10-week trial with follow-up at 3 and 6 months after smoking quit date conducted at 12 substance use disorder treatment programs between
Zobrazit všechny související dokumenty

Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..

Obraťte se na technický servis.